Companies/AbCellera Biologics Inc.

Company profile

AbCellera Biologics Inc.

NASDAQ: ABCL · Healthcare · Biotechnology

Canadian filerHQ Vancouver, BCCIK 0001703057Reports USD

#379 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

54D

FH 55DQ 52GM 48SS 65

v0.1 · 65/100 weight · provisional

↑ market scale, revenue growth (YoY) · ↓ 3-yr revenue growth, Piotroski F

Methodology →

Revenue TTM

$79.2M

Rev growth YoY (TTM)

+242.7%

Net income (FY)

-$146.4M

Employees

596

Market cap

$2.5B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$75.1M$75.1M2025

Net income-$146.4M-$146.4M2025

Operating income-$217.1M-$217.1M2025

Total assets$1.4B$1.4B2025

Liabilities$390.0M$390.0M2025

Equity$966.9M$966.9M2025

Revenue trend

FY2021 – FY2025 · USD

$11.6M

FY21

$233.2M

FY21

$375.2M

FY21

$485.4M

FY22

$38.0M

FY23

$28.8M

FY24

$75.1M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

License62%

Research Fees36%

Milestone Payments1%

By geography

CANADA85%

UNITED STATES15%

The read

AbCellera Biologics Inc. booked $75.1M in FY2025 revenue, growing 161% year over year — faster than most Healthcare companies we track, at a -194.9% net margin.

Peers · Healthcare

Extendicare Inc.79B+AxoGen, Inc.80B+Astrana Health, Inc.75B+Heartflow, Inc. Common Stock44D

Key facts

CEOCarl Hansen

SectorHealthcare

IndustryBiotechnology

HeadquartersVancouver, BC

ExchangeNASDAQ: ABCL

Employees596

IPO date2020-12-11

Latest filings

8-K2026-07-06 8-K2026-06-17 8-K2026-06-12 8-K2026-06-05 10-Q2026-05-11 8-K2026-05-11 DEF 14A2026-04-29 10-K2026-02-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.